A lower CNS progression rate following first-generation gefitinib and erlotinib as first-line in brain metastases from EGFR-mutated NSCLC in comparison with chemotherapy (33% vs. 48%) has been reported [45]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.